KR20010052622A - 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 - Google Patents
만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 Download PDFInfo
- Publication number
- KR20010052622A KR20010052622A KR1020007013843A KR20007013843A KR20010052622A KR 20010052622 A KR20010052622 A KR 20010052622A KR 1020007013843 A KR1020007013843 A KR 1020007013843A KR 20007013843 A KR20007013843 A KR 20007013843A KR 20010052622 A KR20010052622 A KR 20010052622A
- Authority
- KR
- South Korea
- Prior art keywords
- ifn
- peg
- ribavirin
- chronic hepatitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract description 41
- 229960000329 ribavirin Drugs 0.000 title claims abstract description 39
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 39
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 208000005176 Hepatitis C Diseases 0.000 title claims abstract description 20
- 208000006154 Chronic hepatitis C Diseases 0.000 title claims abstract description 19
- 208000010710 hepatitis C virus infection Diseases 0.000 title claims abstract description 19
- 229940079322 interferon Drugs 0.000 claims abstract description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 17
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical class CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 19
- 108010047761 Interferon-alpha Proteins 0.000 description 18
- 102000006992 Interferon-alpha Human genes 0.000 description 18
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940065638 intron a Drugs 0.000 description 5
- 238000010606 normalization Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001034834 Homo sapiens Interferon alpha-17 Proteins 0.000 description 1
- 101001034833 Homo sapiens Interferon alpha-21 Proteins 0.000 description 1
- 102100039729 Interferon alpha-21 Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- -1 Polyethylene Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010012770 Rebetron Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98110433 | 1998-06-08 | ||
| EP98110433.4 | 1998-06-08 | ||
| PCT/EP1999/003746 WO1999064016A1 (en) | 1998-06-08 | 1999-05-29 | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057009098A Division KR20050055053A (ko) | 1998-06-08 | 1999-05-29 | 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010052622A true KR20010052622A (ko) | 2001-06-25 |
Family
ID=8232086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007013843A Ceased KR20010052622A (ko) | 1998-06-08 | 1999-05-29 | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 |
| KR1020057009098A Ceased KR20050055053A (ko) | 1998-06-08 | 1999-05-29 | 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057009098A Ceased KR20050055053A (ko) | 1998-06-08 | 1999-05-29 | 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도 |
Country Status (34)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL192364B1 (pl) * | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CZ301182B6 (cs) | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| DE60125377T2 (de) * | 2000-08-07 | 2007-09-27 | Sciclone Pharmaceuticals, Inc., San Mateo | Behandlung von hepatitis c mit thymosin, interferon und ribavirin |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| WO2004002422A2 (en) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| ES2624353T3 (es) * | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| JP2006514038A (ja) * | 2002-12-23 | 2006-04-27 | イデニクス（ケイマン）リミテツド | ３’−ヌクレオシドプロドラッグの生産方法 |
| EP4032897B1 (en) | 2003-05-30 | 2025-01-29 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| US8615282B2 (en) | 2004-07-13 | 2013-12-24 | Dexcom, Inc. | Analyte sensor |
| US20060040944A1 (en) * | 2004-06-23 | 2006-02-23 | Gilles Gosselin | 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CN101242857A (zh) * | 2005-08-15 | 2008-08-13 | 弗·哈夫曼-拉罗切有限公司 | 用于HBV治疗的PEG-IFNa和利巴韦林 |
| US9201979B2 (en) * | 2005-09-14 | 2015-12-01 | Millennial Media, Inc. | Syndication of a behavioral profile associated with an availability condition using a monetization platform |
| JP5254033B2 (ja) * | 2005-12-23 | 2013-08-07 | イデニク プハルマセウティカルス，インコーポレイテッド | 分岐型ヌクレオシドを調製するための合成中間体の製造方法 |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| SG172359A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside phosphoramidates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| ES2537785T3 (es) | 2009-05-08 | 2015-06-12 | Sciclone Pharmaceuticals, Inc. | Péptidos de alfa timosina como potenciadores de vacunas |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| CN102612362A (zh) | 2009-08-05 | 2012-07-25 | 皮里斯股份公司 | 脂质运载蛋白突变蛋白的控制释放制剂 |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| US9549968B2 (en) | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| SMT201900297T1 (it) | 2010-06-08 | 2019-07-11 | Astrazeneca Ab | Muteine di lipocalina lacrimale che si legano a il-4 r alfa |
| CA2808392C (en) | 2010-08-16 | 2020-03-10 | Pieris Ag | Binding proteins for hepcidin |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US9221885B2 (en) | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| SG10201604566QA (en) | 2011-12-13 | 2016-07-28 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140039923A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for receiving and managing patient data gathered during patient treatments |
| KR20200060782A (ko) | 2013-01-31 | 2020-06-01 | 길리애드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| CA2905186A1 (en) | 2013-03-14 | 2014-09-18 | Daiichi Sankyo Co., Ltd | Novel binding proteins for pcsk9 |
| CA2891557A1 (en) | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CN113621050A (zh) | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| AR103714A1 (es) | 2015-02-18 | 2017-05-31 | Sanofi Sa | Proteínas específicas para pioverdina y pioquelina |
| US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| FI3298030T3 (fi) | 2015-05-18 | 2023-02-22 | Pieris Pharmaceuticals Gmbh | Syöpää ehkäisevä fuusiopolypeptidi |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
| SG11201803732PA (en) | 2015-11-30 | 2018-06-28 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| MX2019008434A (es) | 2017-01-18 | 2019-11-11 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina con afinidad de unión por lag-3. |
| AU2019315703A1 (en) | 2018-07-31 | 2020-12-10 | Les Laboratoires Servier | Novel fusion protein specific for CD137 and PD-L1 |
| US12486330B2 (en) | 2019-02-26 | 2025-12-02 | Pieris Pharmaceuticals Gmbh | Fusion proteins specific for CD137 and GPC3 |
| CN116249709A (zh) | 2020-06-05 | 2023-06-09 | 皮里斯制药有限公司 | 靶向4-1bb的多聚体免疫调节剂 |
| EP4320141A1 (en) | 2021-04-08 | 2024-02-14 | Pieris Pharmaceuticals GmbH | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |
| WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
| TW202428603A (zh) | 2022-09-21 | 2024-07-16 | 美商思進公司 | 新穎的cd137及cd228特異性融合蛋白 |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3719046A1 (de) * | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5238915A (en) * | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| ATE214940T1 (de) * | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| AU7473096A (en) * | 1995-11-02 | 1997-05-22 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| PL192364B1 (pl) * | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
-
1999
- 1999-05-29 PL PL344794A patent/PL192364B1/pl unknown
- 1999-05-29 DK DK99927804T patent/DK1087778T3/da active
- 1999-05-29 CA CA002334267A patent/CA2334267C/en not_active Expired - Lifetime
- 1999-05-29 HR HR20000808A patent/HRP20000808A2/hr not_active Application Discontinuation
- 1999-05-29 ES ES99927804T patent/ES2251196T3/es not_active Expired - Lifetime
- 1999-05-29 EP EP99927804A patent/EP1087778B1/en not_active Expired - Lifetime
- 1999-05-29 CZ CZ20004487A patent/CZ298681B6/cs not_active IP Right Cessation
- 1999-05-29 ID IDW20002551A patent/ID29285A/id unknown
- 1999-05-29 KR KR1020007013843A patent/KR20010052622A/ko not_active Ceased
- 1999-05-29 AU AU45033/99A patent/AU767131B2/en not_active Expired
- 1999-05-29 KR KR1020057009098A patent/KR20050055053A/ko not_active Ceased
- 1999-05-29 RS YUP-770/00A patent/RS50144B/sr unknown
- 1999-05-29 RU RU2003119460/14A patent/RU2271217C2/ru active
- 1999-05-29 TR TR2000/03635T patent/TR200003635T2/xx unknown
- 1999-05-29 CN CNB998071706A patent/CN1170543C/zh not_active Expired - Lifetime
- 1999-05-29 JP JP2000553084A patent/JP3839667B2/ja not_active Expired - Lifetime
- 1999-05-29 SI SI9930843T patent/SI1087778T1/sl unknown
- 1999-05-29 AT AT99927804T patent/ATE307597T1/de active
- 1999-05-29 HU HU0102033A patent/HU228218B1/hu unknown
- 1999-05-29 NZ NZ508249A patent/NZ508249A/xx not_active IP Right Cessation
- 1999-05-29 IL IL13978699A patent/IL139786A0/xx active IP Right Grant
- 1999-05-29 WO PCT/EP1999/003746 patent/WO1999064016A1/en not_active Ceased
- 1999-05-29 BR BR9911076-8A patent/BR9911076A/pt not_active Application Discontinuation
- 1999-05-29 DE DE69927971T patent/DE69927971T2/de not_active Expired - Lifetime
- 1999-06-02 SA SA99200208A patent/SA99200208B1/ar unknown
- 1999-06-04 TW TW088109246A patent/TWI241913B/zh not_active IP Right Cessation
- 1999-06-04 AR ARP990102664A patent/AR019855A1/es not_active Application Discontinuation
- 1999-06-04 PE PE1999000478A patent/PE20000560A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035303A patent/CO5050297A1/es unknown
- 1999-06-07 MY MYPI99002297A patent/MY124091A/en unknown
- 1999-06-08 MA MA25613A patent/MA26641A1/fr unknown
-
2000
- 2000-11-20 IL IL139786A patent/IL139786A/en not_active IP Right Cessation
- 2000-11-21 ZA ZA200006814A patent/ZA200006814B/en unknown
- 2000-12-05 NO NO20006178A patent/NO325598B1/no not_active IP Right Cessation
-
2001
- 2001-11-07 US US10/037,064 patent/US20030053986A1/en not_active Abandoned
-
2004
- 2004-07-26 US US10/899,726 patent/US20050031589A1/en not_active Abandoned
-
2006
- 2006-02-02 JP JP2006025756A patent/JP2006160759A/ja active Pending
-
2007
- 2007-01-24 US US11/657,287 patent/US20070196385A1/en not_active Abandoned
-
2010
- 2010-08-04 CL CL2010000828A patent/CL2010000828A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010052622A (ko) | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 | |
| HUP0301444A2 (hu) | Ribavirin és pegilezett alfa-interferon alkalmazása HCV fertőzés kezelésére szolgáló gyógyszerkészítmény előállítására | |
| US20080317714A1 (en) | Method of Treating Hepatitis B Viral Infection | |
| AU746648B2 (en) | Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C | |
| MXPA00011665A (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c | |
| HK1037981B (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepattis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0105 | International application |
Patent event date: 20001206 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20001206 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20030527 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040630 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20050216 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040630 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20030527 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20050519 |
|
| PJ0201 | Trial against decision of rejection |
Patent event date: 20050519 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20050216 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20060807 Appeal identifier: 2005101003245 Request date: 20050519 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20050519 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20050519 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20030724 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20001206 Patent event code: PB09011R02I |
|
| B601 | Maintenance of original decision after re-examination before a trial | ||
| PB0601 | Maintenance of original decision after re-examination before a trial | ||
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050519 Effective date: 20060807 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20060807 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20050519 Decision date: 20060807 Appeal identifier: 2005101003245 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
| PJ2001 | Appeal |
Patent event date: 20060807 Comment text: Trial Decision on Objection to Decision on Refusal Patent event code: PJ20011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20070628 Appeal identifier: 2006201008224 Request date: 20060908 |
|
| J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060908 Effective date: 20070628 |
|
| PJ1302 | Judgment (patent court) |
Patent event date: 20070704 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 20060908 Decision date: 20070628 Appeal identifier: 2006201008224 Appeal kind category: Appeal against decision to decline refusal |
|
| J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
| PJ2002 | Appeal before the supreme court |
Comment text: Trial Decision on Objection to Decision on Refusal Patent event date: 20060807 Patent event code: PJ20021S01I Request date: 20070719 Appeal identifier: 2007301003127 Appeal kind category: Appeal against decision to decline refusal Decision date: 20071115 |
|
| J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070719 Effective date: 20071115 |
|
| PJ1303 | Judgment (supreme court) |
Comment text: Written Judgment (Supreme Court) Patent event date: 20071119 Patent event code: PJ13031S01D Decision date: 20071115 Appeal kind category: Appeal against decision to decline refusal Request date: 20070719 Appeal identifier: 2007301003127 |